Group 1 - The company Qisheng Technology announced that its 34th meeting of the third board of directors will be held on October 24, 2025, to review documents including a proposal for providing guarantees for its controlling subsidiary [1] - The Chinese innovative pharmaceutical industry has sold overseas licenses worth $80 billion this year, indicating a strong performance in the secondary market for biomedicine [1] - Despite the robust activity in the secondary market, the primary market is experiencing a cooling in fundraising, as noted by Lu Gang, a partner at Chuangdong Investment [1]

Group 1 - The company Jingrui Electric Materials (SZ 300655) held its 10th meeting of the 4th board of directors on October 23, 2025, to review the proposal for the "2025 Q3 Report" [1] - As of the report date, Jingrui Electric Materials has a market capitalization of 14.9 billion yuan [2]

截至发稿，南矿集团市值为33亿元。 每经AI快讯，南矿集团（SZ 001360，收盘价：16.39元）10月23日晚间发布公告称，公司2025年1-9月 计提信用减值准备及资产减值准备将减少2025年1-9月利润总额约2341万元，相应减少2025年9月末所有 者权益。2025年1-9月计提信用减值准备及资产减值准备未经会计师事务所审计。 2025年1至6月份，南矿集团的营业收入构成为：制造业占比99.61%，其他业务占比0.39%。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 曾健辉） ...

Group 1 - The company Fulede (SZ 301297) announced that its 23rd meeting of the second board of directors will be held on October 23, 2025, in a communication format, where the profit distribution plan for the first three quarters of 2025 will be reviewed [1] - For the year 2024, Fulede's revenue composition is 100% from professional technical services [1] - As of the report, Fulede's market capitalization is 29.9 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a discussion on why the primary market is facing fundraising difficulties despite the hot secondary market in the biopharmaceutical industry [1]

Group 1 - The core point of the article is that Sanor Bio (SZ 300298) held its 20th meeting of the 5th board of directors on October 23, 2025, to review the proposal for the Q3 2025 report [1] - For the first half of 2025, Sanor Bio's revenue composition shows that medical devices accounted for 99.66% of total revenue, while other sources contributed 0.34% [1] - As of the report date, Sanor Bio has a market capitalization of 10.8 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing deals this year, indicating a vibrant secondary market in biomedicine [1] - There is a discussion on why the primary market is facing challenges in fundraising despite the hot secondary market, as highlighted by an interview with Lu Gang, a partner at Chuangdong Investment [1]

Core Viewpoint - Maipu Medical announced the convening of its board meeting to review the Q3 2025 report, indicating ongoing corporate governance and financial oversight [1] Company Summary - Maipu Medical's revenue composition for the year 2024 is as follows: 97.51% from implantable medical devices and 2.49% from other sources, highlighting a strong focus on its core product line [1] - As of the latest update, Maipu Medical has a market capitalization of 4.7 billion yuan, reflecting its position in the market [1] Industry Summary - The Chinese innovative drug sector has seen significant overseas licensing deals, totaling 80 billion USD this year, indicating a robust international interest in Chinese biopharmaceuticals [1] - Despite the hot secondary market for biomedicine, the primary market is experiencing a cooling in fundraising, suggesting a divergence in market dynamics [1]

Group 1 - The core point of the article is that shareholder Zheng Anmin plans to reduce his stake in Haitai Xinguang by up to approximately 3.28 million shares, which represents no more than about 2.73% of the company's total share capital, within three months after the announcement [1] - Haitai Xinguang's revenue composition for the year 2024 is as follows: 77.94% from medical device manufacturing, 21.55% from the optical medical industry, and 0.51% from other businesses [1] - As of the report, Haitai Xinguang has a market capitalization of 6.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market in biomedicine [1] - There is a discussion about the cooling of fundraising in the primary market for biomedicine, despite the active secondary market [1]

每经AI快讯，中亦科技（SZ 301208，收盘价：40.35元）10月23日晚间发布公告称，公司第五届第八次 董事会会议于2025年10月23日在公司会议室以现场结合通讯的方式召开。会议审议了《关于 <北京中亦 安图科技股份有限公司2025年第三季度报告> 的议案》等文件。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 王晓波） 2025年1至6月份，中亦科技的营业收入构成为：银行占比48.11%，其他金融机构占比26.57%，其他行 业占比17.76%，制造占比3.94%，政府占比3.61%。 截至发稿，中亦科技市值为48亿元。 ...

Group 1 - The core point of the article is that Dipu Technology (SZ 300768) held its 11th meeting of the third board on October 23, 2025, to review the proposal for the company's Q3 2025 report [1] - For the first half of 2025, Dipu Technology's revenue composition is as follows: 28.58% from operators, 24.9% from other businesses, 16.65% from government, 15.64% from public utilities, and 14.24% from finance [1] - As of the report date, Dipu Technology has a market capitalization of 14.9 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine [1] - The conversation with Lu Gang, a partner at Chuangdongfang Investment, highlights the contrast between the booming secondary market and the cooling fundraising environment in the primary market [1]

Group 1 - The core point of the article is that Xinyin Electronics (SZ 301329) held its fourth board meeting of the sixth session on October 23, 2025, to discuss the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Xinyin Electronics reported that its revenue was entirely derived from the electronic component manufacturing industry, accounting for 100.0% of its total revenue [1] - As of the time of reporting, Xinyin Electronics has a market capitalization of 3.7 billion yuan [1] Group 2 - The article also highlights that the Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a robust secondary market for biomedicine, while the primary market is experiencing a fundraising slowdown [1]